Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Operating Leases Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Pacira BioSciences (PCRX) Non-Current Deffered Revenue (2016 - 2022)

Pacira BioSciences has reported Non-Current Deffered Revenue over the past 10 years, most recently at $10.1 million for Q1 2022.

For Q1 2022, Non-Current Deffered Revenue changed N/A year-over-year to $10.1 million; the TTM value through Mar 2022 reached $10.1 million, changed N/A, while the annual FY2021 figure was $10.1 million, N/A changed from the prior year.
Non-Current Deffered Revenue for Q1 2022 was $10.1 million at Pacira BioSciences, roughly flat from $10.1 million in the prior quarter.
Over five years, Non-Current Deffered Revenue peaked at $10.1 million in Q4 2021 and troughed at $10.1 million in Q4 2021.